$EVOK
Evoke Pharma Inc

2016 Q4 Form 10-K Financial Statement

#000156459017004426 Filed on March 15, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q4 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $820.0K $840.0K $820.0K
YoY Change -2.38% 13.51% 12.33%
% of Gross Profit
Research & Development $1.502M $1.708M $1.838M
YoY Change -12.07% -21.51% -40.49%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.502M $1.708M $1.838M
YoY Change -12.07% -21.51% -51.91%
Operating Profit
YoY Change
Interest Expense -$70.00K $78.42K
YoY Change 600.0% 1227.87%
% of Operating Profit
Other Income/Expense, Net $800.0K
YoY Change
Pretax Income -$1.530M -$2.620M -$2.740M
YoY Change -41.6% -10.27% -28.46%
Income Tax
% Of Pretax Income
Net Earnings -$1.527M -$2.624M -$2.735M
YoY Change -41.8% -10.13% -28.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$124.1K -$367.5K -$422.2K
COMMON SHARES
Basic Shares Outstanding 12.35M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.010M $8.690M $10.74M
YoY Change 3.68% -38.63% -11.82%
Cash & Equivalents $9.007M $8.691M $10.74M
Short-Term Investments
Other Short-Term Assets $7.997K $830.0K $940.0K
YoY Change -99.04% 414.14% -16.81%
Inventory
Prepaid Expenses $833.3K
Receivables
Other Receivables
Total Short-Term Assets $9.283M $9.524M $11.67M
YoY Change -2.54% -37.54% -12.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $7.997K $10.00K
YoY Change 25.05% -84.92% -87.89%
Total Long-Term Assets $7.221K $7.997K $10.00K
YoY Change -9.7% -84.92% -87.89%
TOTAL ASSETS
Total Short-Term Assets $9.283M $9.524M $11.67M
Total Long-Term Assets $7.221K $7.997K $10.00K
Total Assets $9.290M $9.532M $11.68M
YoY Change -2.54% -37.7% -12.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $480.0K $930.0K $1.340M
YoY Change -48.39% -7.92% 27.62%
Accrued Expenses $930.0K $760.0K $670.0K
YoY Change 22.37% 8.57% 4.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $146.1K $0.00
YoY Change -100.0% 15.18%
Total Short-Term Liabilities $1.410M $1.834M $2.006M
YoY Change -23.14% -0.73% 19.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.233M $4.369M
YoY Change -100.0% 0.87%
Other Long-Term Liabilities $4.100M
YoY Change
Total Long-Term Liabilities $4.100M $4.233M $4.369M
YoY Change -3.14% 0.87% 43587.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.410M $1.834M $2.006M
Total Long-Term Liabilities $4.100M $4.233M $4.369M
Total Liabilities $5.510M $6.067M $6.375M
YoY Change -9.19% 0.38% 274.96%
SHAREHOLDERS EQUITY
Retained Earnings -$58.81M -$48.06M -$45.44M
YoY Change 22.36% 33.73% 37.61%
Common Stock $62.60M $51.53M $50.74M
YoY Change 21.49% 14.18% 8305004.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.788M $3.465M $5.308M
YoY Change
Total Liabilities & Shareholders Equity $9.294M $9.532M $11.68M
YoY Change -2.5% -37.42% -12.76%

Cashflow Statement

Concept 2016 Q4 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$1.527M -$2.624M -$2.735M
YoY Change -41.8% -10.13% -28.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.370M -$2.460M -$2.500M
YoY Change -44.31% -2.38% -36.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 400.0K 3.360M
YoY Change -102.5% -91.11% 8300.0%
NET CHANGE
Cash From Operating Activities -1.370M -2.460M -2.500M
Cash From Investing Activities
Cash From Financing Activities -10.00K 400.0K 3.360M
Net Change In Cash -1.380M -2.060M 860.0K
YoY Change -33.01% -204.04% -122.22%
FREE CASH FLOW
Cash From Operating Activities -$1.370M -$2.460M -$2.500M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Assets Current
AssetsCurrent
9524431
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7997
CY2015Q4 us-gaap Assets
Assets
9532428
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
927606
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
760782
CY2016Q4 evok Warrant Liability
WarrantLiability
4095019
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15388325
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-554014
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Trading Symbol
TradingSymbol
EVOK
CY2016 dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6485794
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58809143
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3787638
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9294330
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-276715
CY2016 us-gaap Operating Expenses
OperatingExpenses
10544425
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-303160
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-268029
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3592825
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12350360
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12350360
CY2016 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6951600
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-10544425
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
256113
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1235
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
62595546
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169800
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1504356
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
315916
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5464654
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9338068
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016Q2 dei Entity Public Float
EntityPublicFloat
35800000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8691155
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
833276
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7997
CY2016Q4 us-gaap Assets Current
AssetsCurrent
9282779
CY2016 evok Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13168803
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9023658
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5031184
CY2016 evok Financing Costs Related To Warrant Liability
FinancingCostsRelatedToWarrantLiability
533692
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-597615
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14155809
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
9188664
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1504356
CY2016 us-gaap Interest Paid
InterestPaid
169813
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4723572
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1706524
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
98742
CY2016 evok Stock Issued During Period Value Issuance Of Common Stock And Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants
8803036
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
206825
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1706524
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
120889
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
55883
CY2015 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
12313
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-98185
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-20486
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8707742
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10495838
CY2016 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
4500000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
354855
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5031184
CY2015 us-gaap Interest Paid
InterestPaid
230313
CY2015 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
137812
CY2016 evok Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
369863
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also relies on clinical research organizations (&#8220;CROs&#8221;) to manage and recruit subjects for its clinical trials.&nbsp;&nbsp;If these CROs are unable to continue managing the clinical trials, or are unable to recruit the sufficient number of subjects, the delays could adversely affect the completion of the trials and the timing of the filing of the Company&#8217;s NDA with FDA.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#8217;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet clinical trial supply demand for its product candidate and the development of the product candidate could be materially and adversely affected. </p></div>
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193
CY2016 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2015 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2016 evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
CY2016 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P2Y
CY2016 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-12-31
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
116000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
81000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
135000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
139000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2016 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
CY2016 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2016 evok Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3227876
CY2016 evok Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
22881
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3323876
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
16.73
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P11M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1275624
CY2016 evok Class Of Warrant Or Right Issued In Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInPeriodWeightedAverageExercisePrice
2.81
CY2016 evok Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
5.90
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.29
CY2016 evok Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P5Y15D
CY2016 evok Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P8Y
CY2016 evok Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y11M16D
CY2016 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
2.02
CY2015 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
3.30
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.03
CY2016Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
37463
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
30000
CY2016Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
99000
CY2015Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
170000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1800000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1037500
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
628801
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
78854
CY2015Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
41530
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5265764
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1276765
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
CY2016Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
P21Y
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
7700
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.02
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2016 evok Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant Liability Adjustment
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrantLiabilityAdjustment
0.06
CY2016 evok Effective Income Tax Rate Reconciliation Stock Issuance Costs
EffectiveIncomeTaxRateReconciliationStockIssuanceCosts
0.05
CY2016 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.03
CY2015 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.04
CY2016 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.33
CY2015 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.39
CY2016 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.05
CY2015 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.03
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20500000
CY2016 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50
CY2016 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2500000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
201000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
276000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
539000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
430000
CY2016Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
130000
CY2015Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
124000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
870000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
830000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
870000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
830000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1961595
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1961595
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2016 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2015076
CY2016Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2095149
CY2016Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1339343
CY2016Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1502032
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1137753
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
802655
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
830092
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
822325
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
198945
CY2016Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-796560
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3225409
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2970498
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3025281
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-1527343
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7168005
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7217577
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10614692
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12305360
CY2015Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2419961
CY2015Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2188138
CY2015Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1837743
CY2015Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1708302
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1025261
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
976418
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
819703
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
842777
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3520748
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3241163
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2735400
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-2624152
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6103783
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6212803
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6494845
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7123163

Files In Submission

Name View Source Status
0001564590-17-004426-index-headers.html Edgar Link pending
0001564590-17-004426-index.html Edgar Link pending
0001564590-17-004426.txt Edgar Link pending
0001564590-17-004426-xbrl.zip Edgar Link pending
evok-10k_20161231.htm Edgar Link pending
evok-20161231.xml Edgar Link completed
evok-20161231.xsd Edgar Link pending
evok-20161231_cal.xml Edgar Link unprocessable
evok-20161231_def.xml Edgar Link unprocessable
evok-20161231_lab.xml Edgar Link unprocessable
evok-20161231_pre.xml Edgar Link unprocessable
evok-ex1024_664.htm Edgar Link pending
evok-ex1025_826.htm Edgar Link pending
evok-ex1026_665.htm Edgar Link pending
evok-ex231_7.htm Edgar Link pending
evok-ex311_8.htm Edgar Link pending
evok-ex312_11.htm Edgar Link pending
evok-ex321_12.htm Edgar Link pending
evok-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017031516133853939832.jpg Edgar Link pending
g2017031516133859639833.jpg Edgar Link pending
g2017031516133874739836.jpg Edgar Link pending
g2017031516134372038440.jpg Edgar Link pending
g2017031516134463338441.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending